Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 16/20 | 1.00 |
| ▸ | PDE4A | P27815 | 4/20 | 0.77 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.77 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.77 |
| ▸ | PDE3B | Q13370 | 6/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 6/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1743098 | 1.00 | PDE5A (1.00) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL437200 | 1.00 | PDE5A (1.00) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16299617 | 0.89 | PDE5A (0.81) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10201620 | 0.89 | PDE5A (0.84) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL715790 | 0.89 | PDE5A (0.80) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL715788 | 0.89 | PDE5A (0.80) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL715789 | 0.89 | PDE5A (0.80) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13443315 | 0.87 | PDE5A (0.81) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10201496 | 0.87 | PDE5A (1.00) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1961411 | 0.85 | PDE5A (0.75) | PDE5APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-6469016-B1 | VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION | VIVUS, INC. | 2002-10-22 | — | — | US | claimed |
| US-20200223871-A1 | Arginase Inhibitors and Methods of Use | ASTRAZENECA AB (SE) | 2020-07-16 | — | — | US | disclosed |
| EP-2389352-B1 | ARGINASE INHIBITORS AND METHODS OF USE | UNIV PENNSYLVANIA (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20190127395-A1 | Arginase Inhibitors and Methods of Use | ASTRAZENECA AB (SE) | 2019-05-02 | — | — | US | disclosed |
| WO-2016161086-A1 | METHODS AND COMPOSITIONS FOR TREATING GLYCOGEN STORAGE DISEASES USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | DUKE UNIVERSITY (US) | 2016-10-06 | — | — | WO | disclosed |
| US-9447122-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2016-09-20 | — | — | US | disclosed |
| US-20160039847-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2016-02-11 | — | — | US | disclosed |
| US-8894970-B2 | Arginase inhibitors and methods of use thereof | CORRIDOR PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140128399-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | DUKE UNIVERSITY (US) | 2014-05-08 | — | — | US | disclosed |
| US-20050143388-A1 | Nitric oxide donors for treatment of disease and injury | NIH - DEITR | 2005-06-30 | — | — | US | disclosed |
| EP-1469852-A2 | NITRIC OXIDE DONORS FOR TREATMENT OF DISEASE AND INJURY | HENRY FORD HEALTH SYSTEM (US) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003056899-A9 | NITRIC OXIDE DONORS FOR TREATMENT OF DISEASE AND INJURY | FORD HENRY HEALTH SYSTEM (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20040014761-A1 | Treatment of female sexual dysfunction with phosphodiesterase inhibitors | VIVUS, INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003056899-A2 | NITRIC OXIDE DONORS FOR TREATMENT OF DISEASE AND INJURY | HENRY FORD HEALTH SYSTEM (US) | 2003-07-17 | — | — | WO | disclosed |
| US-6476037-B1 | L-arginine and phosphodiesterase (PDE) inhibitor synergism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-11-05 | — | — | US | disclosed |
| US-6403597-B1 | PRETREATMENT SEXUAL INTERCOURSE | VIVUS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | disclosed |
| US-6127363-A | FOR TRANSURETHRAL OR TRANSDERMAL ADMINISTRATION OR INTRACAVERNOSAL INJECTION, KITS | VIVUS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223871-A1 | Arginase Inhibitors and Methods of Use | ARG1, ARG2, NOS2 | PDE5A 56/4885PDE4A 191/4885PDE4B 200/4885 |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | PDE5A, PDE3B, PDE3A | PDE5A 1/4885PDE4A 5/4885PDE4B 8/4885 |
| US-20190127395-A1 | Arginase Inhibitors and Methods of Use | ARG1, ARG2, NOS2 | PDE5A 56/4885PDE4A 191/4885PDE4B 200/4885 |
| US-20040014761-A1 | Treatment of female sexual dysfunction with phosphodiesterase inhibitors | PDE3A, PDE3B, PDE12 | PDE5A 4/4885PDE4A 6/4885PDE4B 10/4885 |
| US-20160039847-A1 | Arginase Inhibitors and Methods of Use Thereof | ARG1, ARG2, PRMT1 | PDE5A 71/4885PDE4A 162/4885PDE4B 225/4885 |
| US-20140128399-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | PDE7A, PDE8A, PDE8B | PDE5A 22/4885PDE4A 6/4885PDE4B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.